<DOC>
	<DOCNO>NCT00977119</DOCNO>
	<brief_summary>The purpose study identify possible genetic polymorphism contribute specific toxicity associate capecitabine ( hand-foot syndrome , diarrhea , neutropenia ) . Additionally , study look gene polymorphisms patient experience toxicity interest , frequency polymorphism difference drug metabolism .</brief_summary>
	<brief_title>Investigation Genetic Determinants Capecitabine Toxicity</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<criteria>woman breast cancer single agent capecitabine therapy consider age 18 year old patient previously receive capecitabine exclude patient receive capecitabine combination another cancer chemotherapy ; concurrent use trastuzumab permit ; concurrent use zoledronic acid allow serum albumin less 3.0 g/dL within last 30 day creatinine clearance ( CrCL ) glomerular filtration rate ( GFR ) less 60 mL/min [ /body surface area ( BSA ) ] ( within last 30 day ) inability understand give inform consent participate patient history inflammatory bowel disease require therapy patient chronic diarrhea syndrome paralytic ileus patient prior concurrent pelvic irradiation patient use ostomy fecal excretion limit number prior chemotherapy ; decision use capecitabine determine solely treat physician</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>capecitabine</keyword>
</DOC>